Results 81 to 90 of about 147,268 (335)

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Targeting Raised von Willebrand Factor Levels in Liver Diseases: Opening Up Newer Therapeutic Avenues

European Medical Journal Hepatology, 2020
Raised levels of the blood coagulation protein von Willebrand factor (VWF) are now recognised to be important in patients with liver disease. The markedly raised plasma VWF levels in patients with acute liver failure and acute-on-chronic liver failure ...
Ashish Goel, Sukesh C. Nair, Uday Zachariah, Kunissery A. Balasubramanian, Ian Mackie, Elwyn Elias   +5 more
doaj   +1 more source

The Yin and Yang of Von Willebrand Factor in Thrombosis and Hemostasis: Lessons from Von Willebrand Disease and Thrombotic Thrombocytopenic Purpura

, 2017
Various factors, including platelets, endothelial cells, and coagulation factors, regulate the mechanisms of thrombosis and hemostasis. Von Willebrand factor (VWF) is one of the key molecules to initiate platelets adhesion and aggregation.
Makoto Kaneko, Isaku Shinzato, Toshiro Takafuta   +2 more
core   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source

Plasma Level of von Willebrand Factor Propeptide at Diagnosis: A Marker of Subsequent Renal Dysfunction in Autoimmune Rheumatic Diseases

Clinical and Applied Thrombosis/Hemostasis, 2020
Introduction: Patients with systemic autoimmune rheumatic diseases (SARDs) such as rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, and systemic sclerosis, which are chronic inflammatory diseases, are prone to develop renal ...
Noritaka Yada, Kiyomi Yoshimoto, Hiromasa Kawashima, Ryo Yoneima, Nobushiro Nishimura, Yoshiaki Tai, Emiko Tsushima, Makiko Miyamoto, Shiro Ono, Masanori Matsumoto, Takashi Fujimoto, Kenji Nishio   +11 more
doaj   +1 more source

Current management of von willebrand disease and von willebrand syndrome

, 2014
Purpose of Review: Anesthesiologists frequently care for patients with altered hemostasis and coagulation. Where a clear history of familial and personal bleeding exists, a thoughtful plan can be developed in advance to manage the issue perioperatively ...
Korshin, Andre, Derham, Jeffrey, Stone, Marc E., Mazzeffi, Michael   +3 more
core   +1 more source

von Willebrand disease and aging: an evolving phenotype [PDF]

, 2014
Item does not contain fulltextBACKGROUND: Because the number of elderly von Willebrand disease (VWD) patients is increasing, the pathophysiology of aging in VWD has become increasingly relevant. OBJECTIVES: To assess age-related changes in von Willebrand
Bom, J.G. Van Der, Giezenaar, M.A., Meijer, K., Eikenboom, J, Laros, B.A.P., Laros-van Gorkom, B. A. P., Leebeek, F. W. G., Ypma, P. F., Leebeek, Frank, Meijer, K; id_orcid, Laros-van Gorkom, B.A.P., Sanders, YV, Giezenaar, M A, Leebeek, FWG, Wi, N.s.g., Sanders, Yvonne, Mauser-Bunschoten, EP, Sanders, Y. V., Ypma, P.F., Ypma, PF, Cnossen, M. H., Nijziel, MR, Giezenaar, M. A., Mauser-Bunschoten, E. P., WIN STUDY Grp, Nijziel, M.R., Leebeek, F.W.G., Cnossen, M.H., Cnossen, Marjon, Fijnvandraat, K, Meijer, K, Meijer, K (Karina), Mauser-Bunschoten, E.P., Sanders, Y.V., Meijer, K.; id_orcid, van der Bom, JG, Leebeek, F.W., Fijnvandraat, K., van der Bom, J. G., van der Bom, JG (Anske), Nijziel, M. R., Eikenboom, J., Cnossen, MH, Leebeek, Frank; id_orcid, Laros-van Gorkom, BAP   +44 more
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

Drugs in Context, 2016
Human plasma-derived factor VIII/von Willebrand factor complex concentrates are used to control bleeding in patients with von Willebrand disease (VWD) or haemophilia A (HA).
Paul Harper, Emmanuel J Favaloro, Julie Curtin, Chris Barnes, Scott Dunkley   +4 more
doaj   +1 more source

Von willebrand disease: An overview

Indian Journal of Pharmaceutical Sciences, 2011
Most commonly inherited bleeding disorder, first described in Aland Islands by Erik von Willebrand. It occurs as a result of decrease in plasma levels or defect in von Willebrand factor which is a large multimeric glycoprotein. Monomers of this glycoprotein undergo N-glycosylation to form dimers which get arranged to give multimers. Binding with plasma
Bharati, K. Pavani, Prashanth, U. Ram
openaire   +3 more sources